(NASDAQ: PTGX) Protagonist Therapeutics's forecast annual revenue growth rate of -12.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Protagonist Therapeutics's revenue in 2025 is $207,801,000.On average, 5 Wall Street analysts forecast PTGX's revenue for 2025 to be $7,199,080,109, with the lowest PTGX revenue forecast at $1,891,689,267, and the highest PTGX revenue forecast at $15,706,227,397. On average, 5 Wall Street analysts forecast PTGX's revenue for 2026 to be $11,751,654,704, with the lowest PTGX revenue forecast at $1,239,639,100, and the highest PTGX revenue forecast at $27,814,402,306.
In 2027, PTGX is forecast to generate $6,888,364,569 in revenue, with the lowest revenue forecast at $2,913,151,885 and the highest revenue forecast at $12,232,758,639.